The agreement will see Litmys’ predictive scoring model Rampx use Konovo’s network of more than two million healthcare stakeholders across the US, Europe and Asia to help predict new product potential and commercial viability in early clinical development.

The insights will help life sciences companies get an understanding of whether an approved product is likely to be adopted and what steps can be taken to increase the probability of future commercial success.

The partnership is effective immediately and available to life sciences companies and venture capital firms worldwide. 

Tal Rosenberg, chief executive at Konovo, said: “The life sciences industry has never been under more pressure to validate assets earlier – and with greater precision.

“Konovo’s Intelligent Platform allows Litmys to provide executives, researchers and investors alike with a clearer, earlier understanding of whether an asset can truly succeed commercially after regulatory approval.” 

Harris Kaplan, managing partner at Litmys, added: “Konovo’s Intelligent Platform empowers us to execute the underlying data collection quickly and effectively, allowing us more time to focus on generating the ‘so what’ for our clients.”